Safety of eplerenone for kidney-transplant recipients with impaired renal function and receiving cyclosporine A

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Bertocchio, Jean Philippe ^a,b   Barbe, Coralie ^a   Lavaud, Sylvie ^a   Toupance, Olivier ^a   Nazeyrollas, Pierre ^a   Jaisser, Frederic ^b   Rieu, Philippe ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CYCLOSPORIN A; EPLERENONE; POTASSIUM; RESIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MALE; METABOLIC ACIDOSIS; OPEN STUDY; POTASSIUM BLOOD LEVEL; PREDICTION; PROSPECTIVE STUDY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RENAL INSUFFICIENCY; SAFETY;

ADULT; AGED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; ROC CURVE; SAFETY; SPIRONOLACTONE; TRANSPLANT RECIPIENTS;

EID: 84978903960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153635     Document Type: Article

References (51)

1. Menon MC, Murphy B. Maintenance immunosuppression in renal transplantation. Current opinion in pharmacology. 2013; 13(4):662-71. Epub 2013/06/05. doi: 10.1016/j.coph.2013.05.004 PMID: 23731524.
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349(24):2326-33. Epub 2003/12/12. doi: 10.1056/ NEJMoa020009349/24/2326 [pii]. PMID: 14668458.
3. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4(2):481-508. Epub 2009/02/17. doi: 4/2/481 [pii] doi: 10.2215/CJN.04800908 PMID: 19218475.
4. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 1987; 44(1):135-41. Epub 1987/07/01. PMID: 3603674.
5. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1):11-21. Epub 2010/11/16. doi: 10.1056/NEJMoa1009492 PMID: 21073363.
6. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14):1309-21. Epub 2003/04/02. doi: 10.1056/NEJMoa030207 NEJMoa030207 [pii]. PMID: 12668699.
7. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010; 24 (7):2454-63. Epub 2010/03/20. doi: fj.09-147926 [pii] doi: 10.1096/fj.09-147926 PMID: 20299606.
8. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nature medicine. 2012; 18(9):1429-33. Epub 2012/08/28. doi: 10.1038/nm.2891 PMID: 22922412; PubMed Central PMCID: PMC3491085.
9. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003; 63(1):43-52. Epub 2002/ 12/11. doi: kid707 [pii] doi: 10.1046/j.1523-1755.2003.00707.x PMID: 12472767.
10. Perez-Rojas JM, Derive S, Blanco JA, Cruz C, Martinez de la Maza L, Gamba G, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2005; 289(5):F1020-30. Epub 2005/07/07. doi: 00166.2005 [pii] doi: 10.1152/ajprenal.00166.2005 PMID: 15998842.
11. Nielsen FT, Jensen BL, Marcussen N, Skott O, Bie P. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. Nephrol Dial Transplant. 2008; 23(9):2777-83. Epub 2008/04/22. doi: gfn204 [pii] doi: 10.1093/ndt/gfn204 PMID: 18424460.
12. Sun QL, Li M, Rui HL, Chen YP. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity. Journal of the renin-angiotensinaldosterone system: JRAAS. 2015; 16(2):301-10. Epub 2014/12/17. doi: 10.1177/1470320314561248 PMID: 25500744.
13. Amador CA, Bertocchio JP, Andre-Gregoire G, Placier S, Duong Van Huyen JP, El Moghrabi S, et al. Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. Kidney Int. 2015. Epub 2015/10/01. doi: 10.1038/ki.2015.312 PMID: 26422501.
14. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circulation Heart failure. 2014; 7(1):51-8. Epub 2013/12/04. doi: 10.1161/CIRCHEARTFAILURE.113.000792 PMID: 24297687.
15. Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British journal of clinical pharmacology. 2012; 73(3):447-54. Epub 2011/09/29. doi: 10.1111/j.1365-2125.2011.04102.x PMID: 21950312; PubMed Central PMCID: PMC3370349.
16. Gonzalez Monte E, Andres A, Polanco N, Toribio MJ, Santana R, Gutierrez Martinez E, et al. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. Transplant Proc. 2010; 42 (8):2899-901. Epub 2010/10/26. doi: S0041-1345(10)01224-8 [pii] doi: 10.1016/j.transproceed.2010. 08.024 PMID: 20970564.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. PMID: 2702835.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. PMID: 10075613.
19. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709-17. Epub 1999/09/02. PMID: 10471456.
20. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351(6):543-51. Epub 2004/08/06. doi: 10.1056/NEJMoa040135351/6/543 [pii]. PMID: 15295047.
21. Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. Jama. 2012; 308(20):2097-107. Epub 2012/11/29. doi: 10. 1001/jama.2012.14795 PMID: 23188026.
22. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circulation Heart failure. 2014; 7(4):573-9. Epub 2014/05/09. doi: 10. 1161/CIRCHEARTFAILURE.114.001104 PMID: 24812304.
23. Kaplan B, Wang Z, Abecassis MM, Fryer JP, Stuart FP, Kaufman DB. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation. 1996; 62(8):1174-5. Epub 1996/10/27. PMID: 8900321.
24. Mitterbauer C, Heinze G, Kainz A, Kramar R, Horl WH, Oberbauer R. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant. 2008; 23(5):1742-6. Epub 2008/02/01. doi: 10.1093/ndt/gfm864 PMID: 18234845.
25. Hocherl K, Kees F, Kramer BK, Kurtz A. Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression. Kidney Int. 2004; 65(6):2071-80. Epub 2004/05/20. doi: 10. 1111/j.1523-1755.2004.00627.x PMID: 15149320 .
26. Melnikov S, Mayan H, Uchida S, Holtzman EJ, Farfel Z. Cyclosporine metabolic side effects: association with the WNK4 system. European journal of clinical investigation. 2011; 41(10):1113-20. Epub 2011/03/26. doi: 10.1111/j.1365-2362.2011.02517.x PMID: 21434893.
27. Hoorn EJ, Walsh SB, McCormick JA, Furstenberg A, Yang CL, Roeschel T, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nature medicine. 2011; 17(10):1304-9. Epub 2011/10/04. doi: 10.1038/nm.2497 PMID: 21963515; PubMed Central PMCID: PMC3192268.
28. Zhang Y, Lin DH, Wang ZJ, Jin Y, Yang B, Wang WH. K restriction inhibits protein phosphatase 2B (PP2B) and suppression of PP2B decreases ROMK channel activity in the CCD. American journal of physiology Cell physiology. 2008; 294(3):C765-73. Epub 2008/01/11. doi: 10.1152/ajpcell.00528.2007 PMID: 18184875; PubMed Central PMCID: PMC2734475.
29. Keven K, Ozturk R, Sengul S, Kutlay S, Ergun I, Erturk S, et al. Renal tubular acidosis after kidney transplantation-incidence, risk factors and clinical implications. Nephrol Dial Transplant. 2007; 22 (3):906-10. Epub 2007/01/11. doi: 10.1093/ndt/gfl714 PMID: 17210594.
30. Stahl RA, Kanz L, Maier B, Schollmeyer P. Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: a cyclosporine A associated side effect. Clinical nephrology. 1986; 25(5):245-8. Epub 1986/05/01. PMID: 3521998.
31. Heering P, Grabensee B. Influence of ciclosporin A on renal tubular function after kidney transplantation. Nephron. 1991; 59(1):66-70. Epub 1991/01/01. PMID: 1658670.
32. Tumlin JA, Sands JM. Nephron segment-specific inhibition of Na+/K(+)-ATPase activity by cyclosporin A. Kidney Int. 1993; 43(1):246-51. Epub 1993/01/01. PMID: 8381891.
33. Henger A, Tutt P, Riesen WF, Hulter HN, Krapf R. Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients. J Lab Clin Med. 2000; 136(5):379-89. Epub 2000/11/18. doi: 10.1067/mlc.2000.110371 PMID: 11079465.
34. Dobre M, Rahman M, Hostetter TH. Current status of bicarbonate in CKD. J Am Soc Nephrol. 2015; 26 (3):515-23. Epub 2014/08/26. doi: 10.1681/ASN.2014020205 PMID: 25150154; PubMed Central PMCID: PMC4341479.
35. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, et al. Timing of onset of CKDrelated metabolic complications. J Am Soc Nephrol. 2009; 20(1):164-71. Epub 2008/11/14. doi: 10. 1681/ASN.2008020159 PMID: 19005010; PubMed Central PMCID: PMC2615728.
36. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. Epub 2009/05/06. PMID: 19414839; PubMed Central PMCID: PMC2763564.
37. Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Current hypertension reports. 2014; 16(2):414. Epub 2014/01/11. doi: 10.1007/s11906-013-0414-8 PMID: 24407447.
38. Allen LA, Shetterly SM, Peterson PN, Gurwitz JH, Smith DH, Brand DW, et al. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. Circulation Heart failure. 2014; 7(1):43-50. Epub 2013/11/
39. Smyth A, Dunkler D, Gao P, Teo KK, Yusuf S, O'Donnell MJ, et al. The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. Kidney Int. 2014; 86(6):1205-12. Epub 2014/06/12. doi: 10.1038/ki.2014.214 PMID: 24918156.
40. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. American journal of nephrology. 2009; 30(5):418-24. Epub 2009/09/10. doi: 10. 1159/000237742 PMID: 19738369.
41. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European heart journal. 2012; 33(22):2782-95. Epub 2012/09/04. doi: 10.1093/eurheartj/ ehs257 PMID: 22942339.
42. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011; 79(10):1051-60. Epub 2011/03/18. doi: 10. 1038/ki.2011.48 PMID: 21412221.
43. PMID: 9573535Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int. 1998; 53(5):1209-16. Epub 1998/05/09. doi: 10. 1046/j.1523-1755.1998.00874.x PMID: 9573535.
44. Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol. 2007; 293(1):F2-9. Epub 2007/04/13. doi: 00072.2007 [pii] doi: 10.1152/ajprenal.00072.2007 PMID: 17429034.
45. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, et al. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension. 2014; 63(3):520-6. Epub 2013/12/04. doi: 10.1161/HYPERTENSIONAHA.113.01967 PMID: 24296280.
46. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. Journal of the American College of Cardiology. 2014; 63(6):528-36. Epub 2013/11/05. doi: 10.1016/j.jacc.2013.09. 056 PMID: 24184249.
47. Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. Journal of the American College of Cardiology. 2011; 58(19):1958-66. Epub 2011/10/29. doi: 10.1016/j.jacc.2011.04.049 PMID: 22032706.
48. RALES. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). The American journal of cardiology. 1996; 78(8):902-7. Epub 1996/10/15. PMID: 8888663.
49. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002; 15(8):709-16. Epub 2002/08/06. PMID: 12160194.
50. Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Ohashi H, et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol. 2014; 25(5):1094-102. Epub 2013/12/18. doi: 10. 1681/ASN.2013030273 PMID: 24335969; PubMed Central PMCID: PMC4005296.
51. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015; 372(3):211-21. Epub 2014/11/22. doi: 10.1056/NEJMoa1410853 PMID: 25415805.